520 studies found for:    Open Studies | "Multiple Myeloma"
Show Display Options
Rank Status Study
21 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
22 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
23 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
24 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
25 Not yet recruiting Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
26 Recruiting Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
27 Recruiting Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide, Bendamustine, Prednisone
28 Not yet recruiting Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: VELCADE (Bortezomib);   Drug: Dexamethasone
29 Recruiting A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
30 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
31 Recruiting Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone
32 Recruiting Autologous Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
33 Recruiting A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: LGH447;   Drug: midazolam
34 Recruiting Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy
Condition: Multiple Myeloma
Interventions: Drug: Nelfinavir;   Drug: Lenalidomide;   Drug: Dexamethasone
35 Unknown  Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
Conditions: Multiple Myeloma;   Peripheral Neuropathy
Intervention: Procedure: EMG
36 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
37 Recruiting Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
38 Recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
39 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:
40 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years